Interius BioTherapeutics Develops Wholly Owned Process for Lentiviral Vector Manufacturing; Leverages WuXi Advanced Therapies’ (“WuXi ATU”) plasmid and lentiviral vector manufacturing expertise to advance INT-2104 in vivo CART program for B cell malignancies to the clinic PHILADELPHIA,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.